`
E. Capito et al. / Tetrahedron: Asymmetry 16 (2005) 3232–3240
3237
(1H, m), 7.10–7.24 (5H, m) 7.36 (1H, br d) ppm. 13C
NMR (75.3 MHz, CDCl3) d: 24.2 (CH2), 28.3 (CH3),
29.5 (2CH2), 37.1 (CH2), 53.4 (CH), 56.1 (C), 64.0
(CH2), 126.1 (ArCH), 128.3 (2ArCH), 129.5 (2ArCH),
138.2 (ArC), 172.6 (C@O) ppm. EI-MS (m/z): 311 (M+).
13C NMR (75.3 MHz, CDCl3) d: 24.78 (CH2), 26.75
(CH3), 28.38 (2CH2), 41.78 (CH2), 43.09 (C), 67.27
(CH), 71.84 (CH2), 126.40 (ArCH), 128.40 (2ArCH),
129.44 (2ArCH), 138.18 (ArC), 168.90 (C@N) ppm.
EI-MS (m/z): 293 (M+). C15H19NOS2: C, 61.39; H,
6.53; N, 4.77. Found: C, 61.37; H, 6.50; N, 4.79.
4.3.3.
N-[(1S)-1-(Hydroxymethyl)-2-methylpropyl]-2-
methyl-1,3-dithiane-2-carboxamide 5. Yield: 43%.
[a]D = ꢀ18.6 (c 0.5, CHCl3). 1H NMR (400 MHz,
CDCl3) d: 0.86–0.94 (6H, m), 1.62 (3H, s), 1.73–1.92
(2H, m), 1.99–2.07 (1H, m), 2.63–2.70 (2H, m), 2.83–
2.96 (2H, m), 3.20–3.26 (1H, m), 3.56–3.70 (3H, m),
7.45 (1H, br d, J = 8.9 Hz) ppm. 13C NMR
(75.3 MHz, CDCl3) d: 18.85 (CH3), 20.04 (CH3), 24.33
(CH2), 28.14 (CH3), 28.98 (2CH2), 29.13 (CH), 55.56
(C), 58.16 (CH), 63.70 (CH2), 171.73 (C@O) ppm.
EI-MS (m/z): 263 (M+).
4.4.3.
(4S)-4-Isopropyl-2-(2-methyl-1,3-dithiane-2-yl)-
4,5-dihydro-1,3-oxazole 9. Yield: 81%. [a]D = ꢀ64 (c
1
0.3, CHCl3). H NMR (300 MHz, CDCl3) d: 0.70 (3H,
m), 0.79 (3H, m), 1.53 (3H, m), 1.55–1.74 (2H, m),
1.91–1.98 (1H, m), 2.45 (2H, d, J = 12.89 Hz), 3.04–
3.16 (1H, m), 3.25–3.38 (1H, m), 3.71–3.93 (2H, m),
4.06–4.16 (1H, m) ppm. 13C NMR (75.3 MHz, CDCl3)
d: 18.22 (CH3), 18.57 (CH3), 24.70 (CH2), 26.79 (CH3),
28.18 (2CH2), 33.06 (CH), 42.81 (C), 70.33 (CH2),
72.08 (CH), 168.57 (C@N) ppm. EI-MS (m/z): 245
(M+). C11H19NOS2: C, 53.84; H, 7.80; N, 5.71. Found:
C, 53.81; H, 7.82; N, 5.70.
4.3.4. N-[(1S)-1-(Hydroxymethyl)-2,2-dimethylpropyl]-2-
methyl-1,3-dithiane-2-carboxamide 6. Yield: 41%. 1H
NMR (300 MHz, CDCl3) d: 0.98 (9H, s), 1.72 (3H, s),
1.79–1.95 (1H, m), 2.03–2.16 (1H, m), 2.38 (br s, 1H),
2.69–2.78 (2H, m), 2.91–3.06 (2H, m), 3.51–3.57 (1H,
m), 3.77–3.84 (1H, m), 3.95 (1H, dd, J = 3.6 Hz,
J = 11.1 Hz), 7.55 (1H, br d, J = 9.1 Hz) ppm. 13C
NMR (75.3 MHz, CDCl3) d: 25.32 (CH2), 27.32
(3CH3), 29.73 (CH3), 34.29 (2CH2), 56.44 (C), 61.54
(CH), 63.98 (CH2), 172.30 (C@O) ppm. EI-MS (m/z):
277 (M+).
4.4.4.
(4S)-4-tert-Butyl-2-(2-methyl-1,3-dithiane-2-yl)-
4,5-dihydro-1,3-oxazole 10. Yield: 60%. [a]D = ꢀ68 (c
1
0.3, CHCl3). H NMR (300 MHz, CDCl3) d: 0.97 (9H,
s), 1.75 (3H, s), 1.81–1.92 (1H, m), 2.12–2.20 (1H, m),
2.61–2.75 (2H, m), 3.25–3.39 (1H, m), 3.42–3.59 (1H,
m), 3.86–3.99 (1H, m), 4.18–4.35 (2H, m) ppm. 13C
NMR (75.3 MHz, CDCl3) d: 24.60 (CH2), 26.15
(3CH3), 27.06 (CH3), 28.42 (CH2), 28.51 (CH2), 34.08
(C), 69.51 (CH2), 75.74 (CH), 167.08 (C@N) ppm. EI-
MS (m/z): 259 (M+). C11H21NOS2: C, 55.56; H, 8.16;
N, 5.40. Found: C, 55.53; H, 8.15; N, 5.42.
4.4. General procedures for the synthesis of oxazoles 7–10
To a solution of the amide (1.2 mmol) in 8.5 mL of
CH2Cl2 were added TsCl (1.8 mmol), Et3N (3.6 mmol)
and DMAP (0.06 mmol). After 18 h at room tempera-
ture, a solution of Na2CO3 10% was added and the mix-
ture stirred for 20 min. The solution was extracted with
CH2Cl2 (3 · 30 mL). The organic phases were dried over
MgSO4, filtered and concentrated. The crude was puri-
fied on column chromatography on silica gel (petroleum
ether/EtOAc 3:1) to afford oxazoles 7–10.
4.5. General procedures for the synthesis of oxazoles 11–
12
To a stirred suspension of 0.18 g (1 mmol) of the carbox-
ylic acid 2 in 3.3 mL of dry CH3CN were added amino
alcohol (1 mmol), triphenylphosphine (0.66 g, 2.5 mmol)
and triethylamine (0.7 mL). The mixture was cooled to
0 ꢁC and then a solution of 0.52 g (2.2 mmol) of hexa-
chloroethane in 2 mL of CH2Cl2 was added slowly.
After 18 h at room temperature, water was added, the
mixture extracted with EtOAc (3 · 15 mL), dried over
MgSO4, filtered and concentrated. The crude was puri-
fied by silica gel column chromatography (petroleum
ether/EtOAc 5:1) to afford the oxazoles 11 and 12.
4.4.1. (4S)-4-Benzyl-2-(1,3-dithian-2-yl)-4,5-dihydro-1,3-
oxazole 7. Yield: 73%. Mp 81.3–83.2 ꢁC [a]D = ꢀ19 (c
1
0.3, CHCl3). H NMR (300 MHz, CDCl3) d: 1.26–1.38
(2H, m), 1.83–1.95 (2H, m), 2.15 (1H, dd, J = 7.7 Hz,
J = 13.7 Hz), 2.57 (1H, dd, J = 5.9 Hz, J = 13.7 Hz),
2.76–2.86 (2H, m), 3.29–3.44 (2H, m), 3.80–3.90 (1H,
m), 4.11 (1H, s), 6.61–6.81 (5H, m) ppm. 13C NMR
(75.3 MHz, CDCl3) d: 25.41 (CH2), 27.08 (2CH2),
37.85 (CH), 41.44 (CH2), 67.75 (CH), 71.81 (CH2),
126.36 (ArCH), 128.71 (2ArCH), 129.69 (2ArCH),
138.31 (ArC), 165.82 (C@N) ppm. EI-MS (m/z): 279
(M+). C14H17NOS2: C, 60.18; H, 6.13; N, 5.01. Found:
C, 60.13; H, 6.10; N, 5.03.
4.5.1. (4S,5S)-4-Methyl-2-(2-methyl-1,3-dithian-2-yl)-5-
phenyl-4,5-dihydro-1,3-oxazole
11. Yield:
78%.
[a]D = +40 (c 0.3, CHCl3). 1H NMR (300 MHz, CDCl3)
d: 1.02 (3H, d, J = 6.76 Hz), 1.29–1.53 (2H, m), 1.86
(3H, s), 1.99–2.10 (2H, m), 3.23–3.41 (2H, m), 3.72–
3.84 (1H, m), 4.55 (1H, d, J = 7.6 Hz), 6.90–7.12 (5H,
m) ppm. 13C NMR (75.3 MHz, CDCl3) d: 21.29
(CH2), 24.42 (CH3), 26.92 (2CH2), 28.19 (CH3), 42.70
(C), 70.89 (CH), 88.24 (CH), 125.55 (2ArCH), 128.14
(2ArCH), 128.88 (ArCH), 141.57 (ArC), 167.96 (C@N)
ppm. EI-MS (m/z): 293 (M+). C15H19NOS2: C, 61.39;
H, 6.53; N, 4.77. Found: C, 61.37; H, 6.50; N, 4.75.
4.4.2.
(4S)-4-Benzyl-2-(2-methyl-1,3-dithian-2-yl)-4,5-
dihydro-1,3-oxazole 8. Yield: 90%. Mp 38.4–39.6 ꢁC
[a]D = ꢀ28 (c 0.3, CHCl3). 1H NMR (300 MHz, CDCl3)
d: 1.43–1.51 (2H, m), 1.71 (3H, s), 2.04–2.15 (2H, m),
2.30 (1H, dd, J = 7.7 Hz, J = 13.8 Hz), 2.69 (1H, dd,
J = 5.9 Hz, J = 13.8 Hz), 3.21–3.30 (2H, m), 3.44–3.60
(2H, m), 3.92–4.03 (1H, m), 6.84–7.00 (5H, m) ppm.
4.5.2.
(4R,5R)-4-Methyl-2-(2-methyl-1,3-dithian-2-yl)-
4,5-diphenyl-4,5-dihydro-1,3-oxazole 12. Yield: 72%.
Mp 102.5–103.1 ꢁC. [a]D = +77 (c 0.3, CHCl3). 1H